Hours

Minutes

Seconds

-40%

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	1,845.00 ₩	-1.70%	23,311
15/06/26	1,877.00 ₩	+2.07%	7,353
12/06/26	1,839.00 ₩	+1.88%	13,127
11/06/26	1,805.00 ₩	-1.63%	6,003
10/06/26	1,835.00 ₩	+0.38%	5,516

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 15/06/2026			5-day change	1st Jan Change
1,877.00 ^KRW	+2.07%		+2.85%	-62.46%

05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	20.36B 13.46M 11.6M 10.68M 10.02M 18.82M 1.27B 19.01M 126M 49.31M 623M 50.52M 49.45M 2.16B	P/E Ratio 2024	-2.12x	P/E Ratio 2025	-9.5x
Enterprise Value	3.17B 2.1M 1.81M 1.66M 1.56M 2.93M 198M 2.96M 19.67M 7.68M 97.05M 7.87M 7.7M 336M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	19.49%	Yield 2024 *	-	Yield 2025	-

05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-15	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
24/06/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
21/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI
14/05/25	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	+2.07%
1 week	+2.85%
Current month	-38.66%
1 month	-38.66%
3 months	-41.71%
6 months	-66.48%
Current year	-62.46%

APTOCROM Inc. Share Price

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,700	1,933
1 month	1,700	2,950
Current year	1,700	5,400
1 year	1,700	11,820
3 years	1,700	49,900
5 years	1,700	113,000
10 years	1,700	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	22/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	22/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	09/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+2.07%	+2.85%	-71.03%	-93.91%	13.7M
ELI LILLY AND COMPANY	+0.14%	-1.20%	+40.04%	+152.61%	1,007B
JOHNSON & JOHNSON	-0.74%	-1.40%	+50.55%	+42.29%	567B
ABBVIE INC.	-0.38%	-2.11%	+15.62%	+59.16%	392B
ROCHE HOLDING AG	-0.35%	+1.05%	+20.91%	+18.37%	328B
NOVARTIS AG	-0.45%	+0.86%	+23.90%	+31.56%	277B
ASTRAZENECA PLC	+0.85%	-2.52%	+22.83%	+12.72%	275B
NOVO NORDISK A/S	-1.62%	+3.97%	-43.75%	-49.23%	196B
AMGEN INC.	-0.25%	+1.72%	+18.59%	+52.62%	189B
GILEAD SCIENCES, INC.	+2.12%	+0.65%	+13.98%	+60.18%	154B
Average	+0.16%	+0.56%	+9.16%	+28.64%	338.61B
Weighted average by Cap.	-0.09%	-0.03%	+27.16%	+67.54%

	2024	2025
Net sales	16.4B 10.84M 9.34M 8.6M 8.07M 15.15M 1.02B 15.31M 102M 39.71M 502M 40.68M 39.82M 1.74B	9.81B 6.48M 5.59M 5.14M 4.82M 9.06M 613M 9.15M 60.8M 23.75M 300M 24.33M 23.81M 1.04B
Net income	-28.09B -18.57M -16.01M -14.73M -13.82M -25.96M -1.76B -26.22M -174M -68.03M -859M -69.69M -68.22M -2.97B	-5.56B -3.68M -3.17M -2.92M -2.73M -5.14M -347M -5.19M -34.46M -13.46M -170M -13.79M -13.5M -589M
Net Debt	-25.07B -16.57M -14.28M -13.14M -12.33M -23.16M -1.57B -23.39M -155M -60.7M -767M -62.18M -60.87M -2.65B	-17.19B -11.36M -9.8M -9.02M -8.46M -15.89M -1.07B -16.04M -107M -41.63M -526M -42.65M -41.75M -1.82B